Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Next Previous
Trial Profile

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 14 Nov 2023 Results of pooled analysis from LOWR-3 , LIMT-1 and LIFT-1, comparing different combinations of novel HDV therapies and assessing their anti-HDV effectiveness, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 27 Jun 2022 According to an Eiger BioPharmaceuticals media release, data from this study were presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022.
  • 26 Jun 2022 Results assessing to characterize HDV RNA, HBV DNA, HBsAg and ALT kinetics during and after lonafarnib and pegylated IFN-Lambda combination therapy, presented at The International Liver Congress 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top